Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has a beta value of 0.47 and has seen 1.26 million shares traded in the last trading session. The company, currently valued at $90.30M, closed the last trade at $0.25 per share which meant it lost -$0.05 on the day or -15.53% during that session. The CYCC stock price is -1132.0% off its 52-week high price of $3.08 and 32.0% above the 52-week low of $0.17.
The consensus among analysts is that Cyclacel Pharmaceuticals Inc (CYCC) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Sporting -15.53% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CYCC stock price touched $0.25 or saw a rise of 31.68%. Year-to-date, Cyclacel Pharmaceuticals Inc shares have moved -32.61%, while the 5-day performance has seen it change 0.88%. Over the past 30 days, the shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) have changed 11.63%.
Wall Street analysts have a consensus price target for the stock at $1, which means that the shares’ value could jump 75.0% from current levels. The projected low price target is $1.0 while the price target rests at a high of $1.0. In that case, then, we find that the current price level is -300.0% off the targeted high while a plunge would see the stock gain -300.0% from current levels.
Cyclacel Pharmaceuticals Inc (CYCC) estimates and forecasts
The company’s shares have lost -42.68% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 57.31% over the past 5 years.
CYCC Dividends
Cyclacel Pharmaceuticals Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 0.01% shares in the company for having 51.82 shares of worth $13130.0 while later fund manager owns 5.8 shares of worth $1468.0 as of Dec 31, 2024 , which makes it owner of about 0.00% of company’s outstanding stock.
